Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription Articles published in Oncol Rep Retrieve available abstracts of 14 articles: HTML format

Single Articles

November 2025
1. NAKAYAMA M, Takagi-Maeda S, Machino Y, Nihira K, et al
   Novel tetravalent bispecific antibody, PSMA/TRAIL?R2 REGULGENT, induces selective tumor cell apoptosis without hepatotoxicity.
   Oncol Rep. 2025;54:155.
   PubMed     Abstract available
   
   
   September 2025
2. WU S, Huang J, Hui K, Yue Y, et al
   [Corrigendum] 2'?Hydroxyflavanone inhibits epithelial?mesenchymal transition, and cell migration and invasion via suppression of the Wnt/beta?catenin signaling pathway in prostate cancer.
   Oncol Rep. 2025;54:102.
   PubMed     Abstract available
   
   
   
3. LI YF, Su S, Luo Y, Wei C, et al
   Widespread activation and critical role of EMT and stemness in the neuroendocrine differentiation of prostate cancer (Review).
   Oncol Rep. 2025;54:109.
   PubMed     Abstract available
   
   
   July 2025
4. LIU C, Tang Y, Wang J, Zhou Y, et al
   Effect of Polygonatum Sibiricum polysaccharides on nude mice model of prostate cancer PC?3 cells.
   Oncol Rep. 2025;54:84.
   PubMed     Abstract available
   
   
   April 2025
5. GUO X, Li S
   Bone metastases of prostate cancer: Molecular mechanisms, targeted diagnosis and targeted therapy (Review).
   Oncol Rep. 2025;53:46.
   PubMed     Abstract available
   
   
   February 2025
6. YANG C, Wang L, Gong C, Lv D, et al
   Antibody?drug conjugates in prostate cancer: Emerging strategies to enhance therapeutic index and current clinical landscape (Review).
   Oncol Rep. 2025;53:21.
   PubMed     Abstract available
   
   
   November 2024
7. ZHOU Y, Ji Z, Yan W, Zhou Z, et al
   [Retracted] Tetramethylpyrazine inhibits prostate cancer progression by downregulation of forkhead box M1.
   Oncol Rep. 2024;52:152.
   PubMed     Abstract available
   
   
   October 2024
8. NOURUZI S, Johnson F, Kumar S, Sivak O, et al
   Targeting adenocarcinoma and enzalutamide?resistant prostate cancer using the novel anti?androgen inhibitor ADA?308.
   Oncol Rep. 2024;52:132.
   PubMed     Abstract available
   
   
   June 2024
9. LIU Y, Qin Z, Yang K, Liu R, et al
   [Corrigendum] Cripto?1 promotes epithelial?mesenchymal transition in prostate cancer via Wnt/beta?catenin signaling.
   Oncol Rep. 2024;51:75.
   PubMed     Abstract available
   
   
   
10. PAN J, Tong F, Ren N, Ren L, et al
    Role of N(6)?methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review).
    Oncol Rep. 2024;51:88.
    PubMed     Abstract available
    
    
    May 2024
11. HSIA YJ, Lin ZM, Zhang T, Chou TC, et al
    Butyrate increases methylglyoxal production through regulation of the JAK2/Stat3/Nrf2/Glo1 pathway in castration?resistant prostate cancer cells.
    Oncol Rep. 2024;51:71.
    PubMed     Abstract available
    
    
    March 2024
12. PARAJULI KR, Jung Y, Taichman RS
    Abscisic acid signaling through LANCL2 and PPARgamma induces activation of p38MAPK resulting in dormancy of prostate cancer metastatic cells.
    Oncol Rep. 2024;51:39.
    PubMed     Abstract available
    
    
    January 2024
13. LEE DY, Chun JN, So I, Jeon JH, et al
    Oncogenic role of FOXM1 in human prostate cancer (Review).
    Oncol Rep. 2024;51:15.
    PubMed     Abstract available
    
    
    December 2023
14. LEE DY, Lee S, Kim YS, Park S, et al
    Cyclosporin A inhibits prostate cancer growth through suppression of E2F8 transcription factor in a MELK?dependent manner.
    Oncol Rep. 2023;50:218.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.